logo
welcome
CNBC

CNBC

Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says

CNBC
Summary
Nutrition label

81% Informative

Prescription fills for weight loss drugs in the U.S. more than doubled in 2024 , according to new data from drug savings company GoodRx.

The figures offer more evidence of the insatiable demand for a buzzy class of medications called GLP-1 and GIP agonists, which have hefty list prices of roughly $1,000 per month before insurance or savings cards.

Zepbound 's jump reflects its first year on the market, as it was approved in November 2023 .

VR Score

86

Informative language

88

Neutral language

43

Article tone

formal

Language

English

Language complexity

51

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Source diversity

1

Affiliate links

no affiliate links